Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefit.
Ganly
Peter
P
Spearing
Ruth
R
D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use*; D009520:New Zealand; D017410:Practice Guidelines as Topic; D011306:Prescription Fees; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*
D016756:Immunoglobulins, Intravenous